Relay Therapeutics is a clinical-stage precision medicine company that sits at the intersection of computational and experimental technologies. The company is focused on making small molecule medicines against precision medicine targets with the objective of making the discovery of medicines both more efficient and effective.
Relay Therapeutics was built upon unparalleled insights into protein motion and how this dynamic behavior relates to protein function. These insights are driven by the company's Dynamo platform, which integrates an array of leading-edge experimental and computational approaches to effectively drug protein targets that have previously been intractable or inadequately addressed.
The company is advancing a pipeline of promising therapeutic candidates, with an initial focus on precision oncology and genetic disease. By leveraging its integrated platform, Relay aims to drug the undruggable and bring life-changing medicines to patients.